– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade –
Shattuck Labs 宣布将在 2024 年美国癌症研究协会 (AACR) 年会上口头展示临床前数据
